Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Bariatric surgery and diabetes remission: Who would have thought it?

Singh AK, Singh R, Kota SK.

Indian J Endocrinol Metab. 2015 Sep-Oct;19(5):563-76. doi: 10.4103/2230-8210.163113. Review.

2.

Roles for the endocannabinoid system in ethanol-motivated behavior.

Henderson-Redmond AN, Guindon J, Morgan DJ.

Prog Neuropsychopharmacol Biol Psychiatry. 2016 Feb 4;65:330-9. doi: 10.1016/j.pnpbp.2015.06.011. Epub 2015 Jun 26. Review.

3.

Role of the endogenous cannabinoid system in nicotine addiction: novel insights.

Gamaleddin IH, Trigo JM, Gueye AB, Zvonok A, Makriyannis A, Goldberg SR, Le Foll B.

Front Psychiatry. 2015 Mar 25;6:41. doi: 10.3389/fpsyt.2015.00041. eCollection 2015. Review.

4.

New trends in the treatment of nicotine addiction.

Sliwińska-Mossoń M, Zieleń I, Milnerowicz H.

Acta Pol Pharm. 2014 Jul-Aug;71(4):525-30. Review.

5.

Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.

McPartland JM, Duncan M, Di Marzo V, Pertwee RG.

Br J Pharmacol. 2015 Feb;172(3):737-53. doi: 10.1111/bph.12944. Review.

6.

Endothelial atypical cannabinoid receptor: do we have enough evidence?

Bondarenko AI.

Br J Pharmacol. 2014 Dec;171(24):5573-88. doi: 10.1111/bph.12866. Review.

7.

The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments.

Kaminski RM, Rogawski MA, Klitgaard H.

Neurotherapeutics. 2014 Apr;11(2):385-400. doi: 10.1007/s13311-014-0266-1. Review.

8.

Cannabinoid signaling and liver therapeutics.

Mallat A, Teixeira-Clerc F, Lotersztajn S.

J Hepatol. 2013 Oct;59(4):891-6. doi: 10.1016/j.jhep.2013.03.032. Epub 2013 Apr 6. Review.

9.

The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake.

Cooper ME, Regnell SE.

Br J Clin Pharmacol. 2014 Jan;77(1):21-30. doi: 10.1111/bcp.12102. Review.

10.

Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials.

Zhou YH, Ma XQ, Wu C, Lu J, Zhang SS, Guo J, Wu SQ, Ye XF, Xu JF, He J.

PLoS One. 2012;7(6):e39062. doi: 10.1371/journal.pone.0039062. Epub 2012 Jun 20. Review.

11.

Utility of biomarkers and imaging in the development of drugs for the treatment of coronary atherosclerosis.

Waters DD.

Can J Cardiol. 2012 Nov-Dec;28(6):687-92. doi: 10.1016/j.cjca.2012.03.003. Epub 2012 May 23. Review.

12.

Cannabinoids and atherosclerotic coronary heart disease.

Singla S, Sachdeva R, Mehta JL.

Clin Cardiol. 2012 Jun;35(6):329-35. doi: 10.1002/clc.21962. Epub 2012 Jan 25. Review.

Supplemental Content

Loading ...
Support Center